4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reaffirmed at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research report report published on Saturday morning,Weiss Ratings reports.

FDMT has been the topic of several other research reports. Chardan Capital restated a “buy” rating and set a $39.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, January 13th. Cantor Fitzgerald lowered 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. Morgan Stanley lowered their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. Finally, Bank of America cut their price objective on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.56.

4D Molecular Therapeutics Trading Down 2.1 %

Shares of FDMT stock traded down $0.10 during trading on Friday, reaching $4.58. 927,608 shares of the company’s stock traded hands, compared to its average volume of 992,118. The firm’s 50-day moving average is $6.66 and its 200 day moving average is $11.49. The company has a market capitalization of $211.73 million, a P/E ratio of -1.61 and a beta of 2.81. 4D Molecular Therapeutics has a 1 year low of $4.50 and a 1 year high of $36.25.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds have recently made changes to their positions in the stock. nVerses Capital LLC purchased a new stake in 4D Molecular Therapeutics during the third quarter valued at about $40,000. Values First Advisors Inc. bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at about $57,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of 4D Molecular Therapeutics by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after buying an additional 3,922 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in 4D Molecular Therapeutics in the third quarter worth approximately $108,000. Finally, Marquette Asset Management LLC purchased a new stake in 4D Molecular Therapeutics in the fourth quarter worth approximately $116,000. 99.27% of the stock is owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.